

Brett Monia, Ionis Pharmaceuticals Inc: Profile & Biography - Bloomberg


































































  





















Feedback





Brett Monia

Senior VP:Antisense Drug Discovery,
Ionis Pharmaceuticals Inc






Career History




Senior VP:Antisense Drug Discovery
Ionis Pharmaceuticals Inc, 12/2015-PRESENT


Senior VP:Drug Discovery
Isis Pharmaceuticals Inc, 1/2012-12/2015


VP:Drug Discovery
Isis Pharmaceuticals Inc, 2/2009-1/2012


VP:Preclinical Drug Discovery
Isis Pharmaceuticals Inc, 10/2000-2/2009


Various Positions
Isis Pharmaceuticals Inc, 10/1989-10/2000


Show More









Website:
www.ionispharma.com






Corporate Information
Address:

2855 Gazelle Court
Carlsbad, CA 92010
United States


Phone:
1-760-931-9200


Fax:
1-619-931-9639


Web url:
www.ionispharma.com











From The Web












Sponsored Financial Commentaries







More From The Web


















Home


News


Top Headlines
Most Popular
Exclusive
Law
Entrepreneurs
Leaders
Economy
Environment
Science
Sports
Markets Magazine
Pursuits Magazine
Bloomberg Visual Data
Bloomberg Best (and Worst)
For comments or complaints about news coverage click here


Regions
U.S.
China
Europe
Asia
U.K. & Ireland
Australia & New Zealand
Canada
India & Pakistan
Japan
Africa
Eastern Europe
Latin America
Middle East
Markets
Commodities
Currencies
Bonds
Stocks
Energy Markets
Municipal Bonds
Emerging Markets
Funds
Islamic Finance
Industries
Energy
Technology
Real Estate
Finance
Health Care
Transportation
Insurance
Retail
Media
Manufacturing




Quick


Market Data


Stocks
Stock Futures
World Indexes
Americas
Europe, Middle East, & Africa
Asia-Pacific
Gainers & Losers
Earnings Calendar
Industry Leaders
Currencies
Americas
Europe, Middle East, & Africa
Asia-Pacific
Foreign Exchange Cross Rates
FX Fixings
Currency Converter
Forex Trading Videos
Commodities
Energy Prices
Metals Prices
Agricultural Prices


Rates & Bonds
US Treasuries
UK Gilts
Germany Bunds
Japan Bonds
Australia Bonds
Bloomberg Bond Indexes
Corporate Bonds
Consumer Rates
Economic Calendar
Watchlist
European Debt Crisis
Symbol Search
The Market Now




Personal Finance


Top Headlines
Saving & Investing
Real Estate
Retirement Planning
Financial Advisers
Taxes
Blog: Ventured & Gained
Real Cost Of
Money Gallery
Calculators
Watchlist (Portfolio Tracker)




Tech


Top Headlines
Social Media
Mobile & Wireless
Web
Enterprise Tech
TV, Games & Movies
Apple
Tech Deals
Global Tech
Slideshows
Videos




U.S. Politics


Sustainability


Top Headlines
Energy
Corporate Sustainability
Policy
Natural Resources
Health & Population
Slideshows
Videos
Blog: The Grid




Luxury


Top Headlines
Autos
Billionaires
Living
Property
Travel
Well Spent
Loot Blog
Pursuits Magazine
Videos




TV


Live TV
Channel Finder
Personalities
Apple TV
iPad App
Schedule
U.S.
Asia
Europe


Shows
Surveillance
Market Makers
Lunch Money
Street Smart
Bloomberg West
Game Changers




Video


Must See
Latest
Live TV
Shows
Playlist




Radio


Live Radio
Shows
Schedule
Personalities
Podcasts
Bloomberg Brief
Featured Podcasts and New Shows
Bloomberg View
Masters in Business
First Word
Surveillance
Bloomberg Advantage
In the Loop
Bloomberg Law
Taking Stock
Bloomberg Best
More Podcasts




Blogs


Global Tech
The Grid
Loot
The Market Now
Political Capital
Tech Deals
Ventured and Gained




Opinion




My Saved



Registration



Sign In



Bloomberg.com



Businessweek.com



Company



About
Blog
Careers
Diversity & Inclusion
News Mission
Philanthropy & Engagement
Press Room
Procurement
Sustainability




Products



Financial Products
Bloomberg Professional Service
Bloomberg Anywhere
Bloomberg Tradebook
Bloomberg Briefs
Bloomberg Indexes
Bloomberg SEF
Service Center
Customer Support
Enterprise Products
Enterprise Solutions
Trading Solutions
Industry Products
Bloomberg BNA
Bloomberg Government
Bloomberg Law
Bloomberg Link
Bloomberg New Energy Finance
Bloomberg Sports
Content Licensing




Bloomberg Anywhere



Mobile Apps



Bloomberg Visual Data






























    Brett Monia | Isis Pharmaceuticals , Inc. | ZoomInfo.com





















 
 
























Browse researchers









For full functionality of ResearchGate it is necessary to enable JavaScript.
            Here are the 
                instructions how to enable JavaScript in your web browser.



   Browse researchers alphabetically by name   This directory shows researcher profiles and public profiles. As a public profile owner, you can opt out from being listed here by changing your Privacy Settings. You can also find profiles of researchers related to you.           A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z   Other    Directory results for A   Alexandre, Gbechoevi to a詹, 小琦    A   Alexandre, Gbechoevi  - Abada, Khairy     Abada, Lyes  - Abbott, el     Abbott, Eleanor  - Abdelazim, Ibrahim     Abdelazim, Ibrahim  - Abdollahzadeh, Leila     Abdollahzadeh, M.  - Abdullah, Mohanad     Abdullah, Mohd  - Abesser, Corinna     Abessi, Ahad  - Aboulfadl, Mehdi     Aboulfadl, Ragia  - Abu Hmeidan, Jareer     Abu Hour, Yousef  - Acevedo Cárdenas, Francisco Xavier     Acevedo Duque, Albeiro  - Acquaye, Aaron     Acquaye, Adolf  - Adams, Rachel     Adams, Rachel  - Adelle, Camilla     Adelli, Archana  - Aditya, Dion     Aditya, Dipta  - af, Lara     af, Latifa  - Agarwal, Anish     Agarwal, Anisha  - Aghbolaghi, Reza     Aghchai, Abdolhossein  - Agui, Juan     Agui, Juan  - Ahad, Mohammed     Ahad, Mohd  - Ahmad, Naveed     Ahmad, Naveed  - Ahmed, Eman       Ahmed, Eman  - Ahmed, Zehra     Ahmed, Zein  - Aina, Emran     Aina, Farah  - Akaha, 應元     Akahad, Now  - Akht, mo     Akhta, Ayee  - Akponah, Ejiro     Akponah, Precious  - Al Hashmi, Haitham     al hashmi, Hamood  - Al-Daasin, Khaled     Al-Daba'een, Faisal  - Al-Rikabi, Hashim     Al-Rikabi, Hussein  - Alali, Mohammed Jasim     Alali, Mohsen  - Alate, Chaitanya     Alate, Monika  - Albertson, Daniel     Albertson, Dawn  - Alderman, Delorus     Alderman, Delton  - Alex, Sandy     Alex, Savatovsky  - Alford, Keith A.     Alford, Kimberly  - Alhussein, Saad     Alhussein, Shalimar  - Ali, Mutari  Hajara     Ali, Mutaz  - Alina, Dumitru     Alina, Emma  - Alkhoury, Ziad     Alkhoushi, Najla  - Allen, Tara     Allen, Tara  - Almeida Figueroa, Leonor       Almeida Filho, Antonio  - Alnasr, Modi     Alnasr, Qasem  - Alqowaifly, Lolowah     Alqoyus, walu  - Alsheikh-Hussain, Areej     Alsheikha, Nour  - Altuntas, Muhammed     Altuntas, Muhammed  - Alves Barbosa, Marcela     Alves Barbosa, Weider  - Alzoubi, Mohammad     Alzoubi, Mohammed  - Amato, Mark     Amato, Marta  - Amighi, Fatemeh     Amighi, Karim  - Ammen, Sean     Ammen, Sue  - an, Junyoung     An, Justin  - Anca, Andreea     Anca, Anton  - Anderson, Ld     Anderson, Lea  - Andrade, Mariane     Andrade, Mariano  - Andrianto, Sonny     Andrianto, Tomy  - Angelopoulou, Elthina     Angelopoulou, Fotini  - Anka, An     Anka, Ann  - Antalek, Brian     Antalek, Mitchell  - Antunes, Filipe     Antunes, Filipe  - Ape, Francesca     Ape, Hendra  - Arab, Raed       Arab, Rahim  - Araujo, Camilo     Araujo, Carla  - Arcila, Angela     Arcila, Annelisa  - Argiro, Renato     Argiro, Salvatore  - Arismendy Mira, Julian Esteban     Arismendy Morales, Juan  - Armstrong-Gibbs, Fiona     Armstrong-Gregson, Julie  - Arouri, Ahmad     Arouri, Faten  - Arsova-Sarafinovska, Zorica     Arsovic, Marjan  - Aryatnie, Yuly     Aryava Parsi, Ardavan  - Asfaw, Asfawossen     Asfaw, Asrat  - Ashwell, Ellie     Ashwell, Felipe  - Asroni, Imam     Asror, Ibnu  - Atalay, Betul     Atalay, Bora  - Atkinson-Hope, Gary     Atkinson-Leadbeater, Karen  - Audi, Winston     Audia, Ale  - Austin, Vivienne     Austin, Walter  - Avit, Gaspar     Avit, Geoffrey  - Ayala Ramírez, Juan     ayala rendon, Carolina  - Ayoub, Fadi     Ayoub, Fadi  - Azevedo, Mario     Azevedo, Marisa  - a詹, 小琦        
© 2008-2017 ResearchGate GmbH. All rights reserved.About us · Help Center · Careers · Developers · News · Contact us · Privacy · Terms · Copyright | Advertising · Recruiting
orDiscover by subject areaJoin for freeLog in   ResearchGate is the professional network for scientists and researchers. Join for free   An error occurred while rendering template.  rgreq-76f01bf7e39691eecd1358847938fa2d false 










 








Brett P. Monia, Ph.D. - Ionis Pharmaceuticals



























































































Brett P. Monia, Ph.D.




Senior Vice President, Antisense Drug Discovery
Dr. Monia is a founding member of Ionis and Senior Vice President of Antisense Drug Discovery. Dr. Monia is also the Franchise Leader for Programs in Oncology and Rare Genetic Diseases at Ionis Pharmaceuticals. As head of Drug Discovery, Dr. Monia is responsible for establishing strategic directions for preclinical drug discovery research focused on RNA-directed therapeutic platforms, establishment and supervision of early clinical development strategies through clinical proof-of-concept, and coordinating research activities with clinical investigators, consultants, and with corporate partners. His contributions include research into the medicinal chemistry and mechanisms of action of oligonucleotide-based drugs in cell culture and in animals, and in the establishment of numerous preclinical and clinical programs in various therapeutic areas, including oncology, metabolic disease, inflammation, cardiovascular disease, and rare diseases.
Programs under Dr. Monia’s direct supervision have resulted in the clinical development of more than twenty antisense-based drugs to date, covering areas as diverse as cancer, type 2 diabetes, cardiovascular disease, asthma, and rare genetic diseases.
Dr. Monia’s publication record exceeds 150 primary research manuscripts, reviews and book chapters, and he is an inventor on more than 100 issued patents. In addition, Dr. Monia serves on the editorial boards for a number of scientific journals, is a member of the American Association of Cancer Research, the American Diabetes Association, the American Association for the Study of Liver Diseases, the American Society of Hematology, and serves on the Board of Directors for the Oligonucleotide Therapeutics Society. Dr. Monia also holds a position as a scientific advisory board member with OncoGenex Technologies, Inc., and is an adjunct professor of biology at San Diego State University where he lectures at the graduate level on pharmacology.
Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and B.S. degrees in Molecular Biology and Analytical Chemistry at Stockton State College, in Pomona, New Jersey.






















About

Mission & Values
In The Community
Management
Board of Directors
Contact


Patients

Patient Resources
Clinical Trials

Drug Approval Process
Learn More About Ionis’ Clinical Trials




Pipeline
R&D

Antisense Technology

Discovery Platform
Basic Science
Antisense Drugs
Medicinal Chemistry
Antisense Approaches


Intellectual Property
Strategic Alliances

Pharmaceutical Partners
Satellite Companies




Investors & Media

News & Events

Press Releases
Archived Webcasts
Event Calendar


Corporate Governance

Board of Directors
Board Criteria
Director Compensation and Board Meeting Attendance
Committee Composition
Certificates of Incorporation
Bylaws
Code of Ethics
Clawback Policy
RSU Holding Guidelines
Annual Meeting


Stock Information

Stock Quote
Stock Chart
Analyst Coverage
Ownership Profile


Financials

Annual Reports
SEC Filings


Shareholder Services

Investor FAQ
Information Request


Press Kit


Careers

Available Positions

Search Open Jobs
Browse Open Jobs
Edit Your Profile
View Submitted Applications


Culture & Values
Benefits
Equal Opportunity
Intern Program
Post-Doctoral Program










Brett P. Monia – Dynacure – Innovative therapies for rare diseases































































Brett P. Monia








 







Brett P. Monia (PhD) is a founding member of Ionis Pharmaceuticals (IONS) and the Executive Officer and Senior Vice President of Antisense Drug Discovery. Dr. Monia is also the Franchise Leader for programs in Oncology and Rare Genetic Diseases at Ionis Pharmaceuticals. As head of Drug Discovery, Dr. Monia is responsible for establishing strategic directions for preclinical drug discovery research, establishing and supervising early clinical development strategies through clinical proof-of-concept, and coordinating research activities with clinical investigators, consultants, and corporate partners. Programs under Dr. Monia’s supervision have resulted in the clinical development of more than 25 antisense-based drugs to date across a broad range of therapeutic areas, including multiple marketing approvals. Dr. Monia’s publication record exceeds more than 200 research manuscripts, reviews, and book chapters, and he is the inventor of more than 100 issued patents. Dr. Monia received his Ph.D. in Pharmacology at the University of Pennsylvania and holds B.S. degrees in Molecular Biology and Analytical Chemistry. He serves on the editorial boards for numerous scientific journals, serves on the Board of Directors as Immediate Past President of the Oligonucleotide Therapeutics Society, and is an adjunct professor of biology at San Diego State University.




 





















				Copyright © 2017 - Dynacure | All Rights Reserved			




 













Supervisory Board – Dynacure – Innovative therapies for rare diseases

























































Supervisory Board




































































				Copyright © 2017 - Dynacure | All Rights Reserved			




 






﻿





























Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Outperform Rating at BMO Capital Markets - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for Ionis Pharmaceuticals Inc.

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor Ionis Pharmaceuticals Inc. with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

Morgan Stanley Reaffirms Overweight Rating for The Charles Schwab Corporation (SCHW)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Outperform Rating at BMO Capital Markets
Celanese Corporation’s (CE) “Neutral” Rating Reaffirmed at UBS AG
Benefitfocus, Inc. (NASDAQ:BNFT) Downgraded to “Hold” at BidaskClub
Total SA (FP) PT Set at €45.00 by Kepler Capital Markets
Asahi Kasei Corp (AHKSY) Stock Rating Upgraded by Zacks Investment Research
Acadia Healthcare Company, Inc. (ACHC) Upgraded by Zacks Investment Research to Buy
Wells Fargo & Company Reiterates Outperform Rating for Alder BioPharmaceuticals, Inc. (ALDR)
Albemarle Corporation to Post FY2020 Earnings of $7.10 Per Share, Jefferies Group Forecasts (NYSE:ALB)
Insider Selling: Nakama Group PLC (NAK) Insider Sells £190,000 in Stock
Innoviva, Inc. (NASDAQ:INVA) Shares Bought by Ameritas Investment Partners Inc.
Sei Investments Co. Has $143,000 Stake in ILG Inc. (NASDAQ:ILG)
Great West Life Assurance Co. Can Holds Position in Infinera Corporation (NASDAQ:INFN)
Swiss National Bank Continues to Hold Position in Green Plains, Inc. (NASDAQ:GPRE)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Shares Sold by JPMorgan Chase & Co.
Ameriprise Financial Inc. Has $5.34 Million Position in IAC/InterActiveCorp (NASDAQ:IAC)
JPMorgan Chase & Co. Cuts Stake in Home BancShares, Inc. (NASDAQ:HOMB)
BTIM Corp. Invests $297,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Quest Diagnostics Incorporated (DGX) Rating Lowered to Hold at BidaskClub
Q4 2017 EPS Estimates for Public Storage (PSA) Reduced by Analyst







Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Outperform Rating at BMO Capital Markets


					Posted by Lucas Kauffman on Jul 25th, 2017 // No Comments




Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)‘s stock had its “outperform” rating restated by investment analysts at BMO Capital Markets in a report released on Tuesday. They presently have a $62.00 target price on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 13.32% from the company’s previous close.
Other analysts also recently issued reports about the stock. Needham & Company LLC  reiterated a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. Piper Jaffray Companies  set a $51.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research report on Wednesday, July 12th. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Finally, Stifel Nicolaus  reissued a “hold” rating and set a $42.00 target price on shares of Ionis Pharmaceuticals in a research note on Monday, July 10th. Three analysts have rated the stock with a sell rating, six have assigned  a hold rating and seven have given a buy rating to the stock. Ionis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $44.55.


 Get Ionis Pharmaceuticals Inc. alerts:



Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded down 8.14% on Tuesday, hitting $54.71. 5,230,093 shares of the stock were exchanged. Ionis Pharmaceuticals has a one year low of $24.58 and a one year high of $60.01. The firm’s 50 day moving average price is $52.42 and its 200 day moving average price is $46.57. The firm’s market cap is $6.78 billion. 





Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, May 9th. The company reported $0.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.13. The firm had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. Ionis Pharmaceuticals’s quarterly revenue was up 199.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.52) EPS.  Equities analysts anticipate that  Ionis Pharmaceuticals will post ($0.27) earnings per share for the current year. 
TRADEMARK VIOLATION NOTICE: This article was first  published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2017/07/25/ionis-pharmaceuticals-inc-nasdaqions-given-outperform-rating-at-bmo-capital-markets.html. 
In related news, SVP Patrick R. O’neil sold 650 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $48.75, for a total transaction of $31,687.50. Following the completion of the sale, the senior vice president now directly owns 10,299 shares in the company, valued at $502,076.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Stanley T. Crooke sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $55.35, for a total transaction of $608,850.00. Following the sale, the chairman now owns 48,014 shares of the company’s stock, valued at $2,657,574.90. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,029 shares of company stock worth $2,384,840. 1.86% of the stock is currently owned by insiders. 
Hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board boosted its stake in  Ionis Pharmaceuticals by 72.4% in the first quarter. Canada Pension Plan Investment Board now owns 111,410 shares of the company’s stock valued at $4,479,000 after buying an additional 46,800 shares in the last quarter.  Janney Montgomery Scott LLC boosted its stake in  Ionis Pharmaceuticals by 12.0% in the first quarter. Janney Montgomery Scott LLC now owns 49,690 shares of the company’s stock valued at $1,998,000 after buying an additional 5,314 shares in the last quarter.  Candriam Luxembourg S.C.A. boosted its stake in  Ionis Pharmaceuticals by 29.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 191,000 shares of the company’s stock valued at $7,679,000 after buying an additional 43,000 shares in the last quarter.  Boston Advisors LLC bought a new stake in  Ionis Pharmaceuticals during the first quarter valued at approximately $354,000.  Finally, BLB&B Advisors LLC boosted its stake in  Ionis Pharmaceuticals by 2.1% in the first quarter. BLB&B Advisors LLC now owns 63,911 shares of the company’s stock valued at $2,569,000 after buying an additional 1,315 shares in the last quarter. Institutional investors and hedge funds own  88.75% of the company’s stock. 
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.







Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 
















































Brett P. Monia - Patents







 


  FREE patent keyword monitoring and additional FREE benefits.  REGISTER now for FREE 
 




    

















  



Browse Inventors:
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z






    SEARCH FreshPatents:   
  | Online Background Check



Brett P. Monia patentsRecent bibliographic sampling of Brett P. Monia patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title): 02/09/17 - 20170035798 - Modulation of factor 11 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein... Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski (Ionis Pharmaceuticals, Inc.)12/22/16 - 20160369275 - Modulation of transthyretin expressionProvided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.... Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo (Ionis Pharmaceuticals, Inc.)12/15/16 - 20160362687 - Methods and compositions for modulating alpha-1 antitrypsin expressionDisclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, A1ATD associated liver... Inventors: Brett P. Monia, Michael L. Mccaleb, Susan M. Freier, Shuling Guo (Ionis Pharmaceuticals, Inc.)12/03/15 - 20150344879 - Compounds and methods for modulating gene expressionThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Inventors: Sanjay Bhanot, Richard S. Geary, Robert Mckay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz (Isis Pharmaceuticals, Inc.)09/24/15 - 20150267195 - Oligomeric compounds comprising bicyclic nucleosides and uses thereofThe present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.... Inventors: Punit P. Seth, Susan M. Freier, Brett P. Monia, Eric E. Swayze (Isis Pharmaceuticals, Inc.)09/10/15 - 20150252367 - Modulation of transthyretin expressionProvided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.... Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo (Isis Pharmaceuticals, Inc.)03/26/15 - 20150087691 - Methods and compositions for modulating alpha-1-antitrypsin expressionDisclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing AIAT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, AIATD associated liver... Inventors: Brett P. Monia, Michael L. Mccaleb, Susan M. Freier, Shuling Guo (Isis Pharmaceuticals, Inc.)02/26/15 - 20150057329 - Compounds and methods for modulating expression apobThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Inventors: Sanjay Bhanot, Richard S. Geary, Robert Mckay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz (Isis Pharmaceuticals, Inc.)12/04/14 - 20140357856 - Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometryThe present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3′-endo conformational geometry (3′-endo regions) or DNA like having southern or C2′-endo/O4′-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in... Inventors: Brett P. Monia, Madeline M. Butler, Robert Mckay, Brenda F. Baker (Isis Pharmaceuticals, Inc.)09/11/14 - 20140256797 - Modulation of transthyretin expressionProvided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.... Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo (Isis Pharmaceuticals, Inc.)07/03/14 - 20140187601 - Antisense oligonucleotide modulation of raf gene expressionOligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided.... Inventors: Brett P. Monia 12/12/13 - 20130331434 - Methods for modulating factor 12 expressionDisclosed herein are methods for decreasing Factor 12 and treating or preventing thromboembolic conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 12 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism,... Inventors: Brett P. Monia, Robert A. Macleod, Jeffrey R. Crosby (Isis Pharmaceuticals, Inc.)11/07/13 - 20130296400 - Antidotes to antisense compoundsThe present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.... Inventors: Brett P. Monia, Andrew M. Siwkowski, Hong Zhang (Isis Pharmaceuticals, Inc.)10/17/13 - 20130274308 - Modulation of factor 11 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein... Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski 07/25/13 - 20130190384 - Modulation of factor 11 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein... Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao, Jeffrey R. Crosby, Andrew M. Siwkowski (Isis Pharmaceuticals, Inc.)06/27/13 - 20130165496 - Compounds and methods for modulating expression of gccrThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Inventors: Sanjay Bhanot, Richard S. Geary, Robert Mckay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz (Isis Pharmaceuticals, Inc.)05/16/13 - 20130123331 - Modulation of diacylglycerol acyltransferase 2 expressionCompounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression... Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-xian Yu, Brett P. Monia (Isis Pharmaceuticals, Inc.)05/02/13 - 20130109849 - Compositions and their uses directed to aceytl-coa carboxylasesDisclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Inventors: Sanjay Bhanot, Brett P. Monia, John G. Geisler, Robert Mckay, Kenneth W. Dobie (Isis Pharmaceuticals, Inc.)03/28/13 - 20130079387 - Antisense oligonucleotide modulation of raf gene expressionOligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided.... Inventors: Brett P. Monia (Isis Pharmaceuticals, Inc.)09/13/12 - 20120232125 - Modulation of diacylglycerol acyltransferase 1 expressionCompounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol... Inventors: Brett P. Monia, Mark J. Graham (Isis Pharmaceuticals, Inc.)08/23/12 - 20120214862 - Modulation of factor 7 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein... Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Chenguang Zhao (Isis Pharmaceuticals, Inc.)08/16/12 - 20120208864 - Compounds and methods for modulating expression of gcgrThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Inventors: Sanjay Bhanot, Richard S. Geary, Robert Mckay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz (Isis Pharmaceuticals, Inc.)08/02/12 - 20120196921 - Modulation of sglt-2 expressionCompounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.... Inventors: Susan M. Freier, Edward Wancewicz, Brett P. Monia, Andrew M. Siwkowski, Lynnetta Watts, Thomas A. Leedom (Isis Pharmaceuticals, Inc.)07/19/12 - 20120184031 - Antisense inhibition via rnase h-independent reduction in mrnaThe present invention provides compositions and methods for reducing levels of a preselected mRNA, using antisense compounds targeted to a splice site or a region up to 50 nucleobases upstream of an exon/intron junction on said mRNA. Preferably, said antisense compounds do not elicit RNAse H cleavage of the mRNA.... Inventors: Brett P. Monia, Susan M. Freier, Muthiah Manoharan, William A. Gaarde, Richard H. Griffey, Eric E.` Swayze, C. Frank Bennett (Isis Pharmaceuticals, Inc.)06/14/12 - 20120149755 - Antisense oligonucleotide modulation of raf gene expressionOligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided.... Inventors: Brett P. Monia (Isis Pharmaceuticals, Inc.)05/10/12 - 20120115930 - Compositions and their uses directed to hepcidinDisclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods... Inventors: Brett P. Monia, C. Frank Bennett, William A. Gaarde, Trisha Lockhart, Robert Mckay (Isis Pharmaceuticals, Inc.)04/05/12 - 20120083522 - Modulation of inflammatory responses by factor xiDisclosed herein are antisense compounds and methods for modulating Factor XI and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be ameliorated or prevented with the administration of antisense compounds targeted to Factor XI.... Inventors: Brett P. Monia, Jeffrey R. Crosby, Robert A. Macleod, Susan M. Freier (Isis Pharmaceuitcals, Inc.)03/29/12 - 20120077862 - Antisense modulation of ptp1b expressionCompounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.... Inventors: Sanjay Bhanot, Lex M. Cowsert, Jacqueline R. Wyatt, Brett P. Monia, Madelline M. Butler, Robert Mckay, Susan M. Freier, Kenneth W. Dobie (Isis Pharmaceuticals, Inc.)02/02/12 - 20120029050 - Compositions and their uses directed to diacylglycerol acyltransferase 1Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a... Inventors: Xing-xian Yu, Sanjay Bhanot, Brett P. Monia (Isis Pharmaceuticals, Inc.)12/01/11 - 20110294868 - Modulation of transthyretin expressionProvided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.... Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski 09/29/11 - 20110237646 - Modulation of transthyretin expression for the treatment of cns related disordersCompounds, compositions and methods are provided for modulating the expression of transthyretin in the brain, specifically the choroid plexus. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with... Inventors: Richard Alan Smith, Brett P. Monia (Isis Pharmaceuticals, Inc.)08/25/11 - 20110207797 - Enhanced antisense oligonucleotidesDescribed herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened... Inventors: Brett P. Monia, Andrew M. Siwkowski, Sanjay Bhanot (Isis Pharmaceuticals, Inc.)07/21/11 - 20110177097 - Methods for modulating expression of crebMethods are provided for modulating CREB by administering a CREB-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of CREB. The present invention is also directed to methods of decreasing lipid levels in a... Inventors: Gerald Shulman, Sanjay Bhanot, Xing-xian Yu, Brett P. Monia 07/14/11 - 20110171730 - Conjugates for use in hepatocyte free uptake assaysThe present invention provides methods of identifying oligomeric compounds, such as siRNA and double-stranded RNA compounds, having bioactivity in vivo, and kits.... Inventors: C. Frank Bennett, Robert Mckay, Brett P. Monia, Brenda F. Baker, Namir Sioufi (Isis Pharmaceuticals, Inc.)06/09/11 - 20110136889 - Compositions and their uses directed to aceytl-coa carboxylasesDisclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Inventors: Sanjay Bhanot, Brett P. Monia, John Geisler, Robert Mckay, Kenneth W. Dobie (Isis Pharmaceuticals Inc.)05/26/11 - 20110123521 - Methods for modulating expression of rbp4Methods are provided for modulating RBP4 by administering a RBP4-specific modulator. Also provided are methods for treating cardiovascular and metabolic disorders in a subject or delaying or preventing risk factors thereof through the modulation of RBP4. The present invention is also directed to methods of decreasing lipid levels in a... Inventors: Brett P. Monia, Xing-xian Yu, Sanjay Bhanot (Isis Pharmaceuticals, Inc)03/10/11 - 20110059895 - Modulation of factor 9 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 9 and increasing clotting time in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 9 include thrombosis, embolism, thromoboembolism such as deep vein thrombosis, pulmonary embolism,... Inventors: Susan M. Freier, Brett P. Monia, Hong Zhang, Chenguang Zhao (Isis Pharmaceuticals, Inc.)12/30/10 - 20100331392 - Antidotes to antisense compoundsThe present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.... Inventors: Brett P. Monia, Andrew M. Siwkowski, Hong Zhang (Isis Pharmaceutical, Inc.)12/23/10 - 20100324122 - Modulation of sglt2 expressionCompounds, compositions and methods are provided for modulating the expression of SGLT2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SGLT2. Methods of using these compounds for modulation of SGLT2 expression and for diagnosis and treatment of diseases and conditions associated with expression of SGLT2 are provided.... Inventors: Susan M. Freier, Edward Wancewicz, Brett P. Monia, Andrew M. Siwkowski, Lynnetta Watts, Thomas A. Leedom (Isis Pharmaceuticals, Inc.)12/09/10 - 20100311810 - Modulation of diacylglycerol acyltransferase 2 expressionCompounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression...  11/25/10 - 20100298417 - Modulation of factor 7 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications, hyperproliferative disorders, or inflammatory conditions in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and...  09/02/10 - 20100222412 - Modulation of glucocorticoid receptor expressionCompounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise antisense compounds, particularly antisense oligonucleotides which have particular in vivo properties, targeted to nucleic acids encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for treatment of diseases...  06/03/10 - 20100137414 - Modulation of factor 11 expressionDisclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein...  02/11/10 - 20100035964 - Antisense modulation of connective tissue growth factor expressionAntisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of...  12/31/09 - 20090326042 - Compounds and methods for modulating expression of crpThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  12/31/09 - 20090326041 - Compounds and methods for modulating expression of sglt2The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  12/24/09 - 20090318532 - Compounds and methods for modulating expression of ptp1bThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  12/10/09 - 20090306357 - Compounds and methods for modulating expression of gccrThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  12/10/09 - 20090306180 - Compounds and methods for modulating expression apobThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  12/10/09 - 20090306179 - Compounds and methods for modulating expression of gcgrThe present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  12/10/09 - 20090306005 - Compounds and methods for modulating expression of pcsk9The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  11/26/09 - 20090292006 - Compounds and methods for modulating expression of dgat2The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are...  10/15/09 - 20090258931 - Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometryThe present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3′-endo conformational geometry (3′-endo regions) or DNA like having southern or C2′-endo/O4′-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in...  05/14/09 - 20090124009 - Antisense modulation of ptp1b expressionCompounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided....  04/23/09 - 20090105177 - Modulation of diacylglycerol acyltransferase 1 expressionCompounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol...  02/26/09 - 20090054359 - Compositions and their uses directed to diacylglycerol acyltransferase 1Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a...  02/05/09 - 20090036355 - Antisense modulation of ptp1b expressionCompositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or de-laying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The...  
Ionis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Isis Pharmaceuitcals, Inc., Isis Pharmaceuticals Inc., Isis Pharmaceuticals, Inc, Isis Pharmaceutical, Inc., Isis Phamaceuticals, Inc.Archived* (*May have duplicates - we are upgrading our archive.)
  	20120214862 - Modulation of factor 7 expression ###The bibliographic references displayed about Brett P. Monia's patents are for a recent sample of Brett P. Monia's publicly published patent applications. The inventor/author may have additional bibliographic citations listed at the USPTO.gov. FreshPatents.com is not associated or affiliated in any way with the author/inventor or the United States Patent/Trademark Office but is providing this non-comprehensive sample listing for educational and research purposes using public bibliographic data published and disseminated from the United States Patent/Trademark Office public datafeed. This information is also available for free on the USPTO.gov website.  If Brett P. Monia filed recent patent applications under another name, spelling or location then those applications could be listed on an alternate page. If no bibliographic references are listed here, it is possible there are no recent filings or there is a technical issue with the listing--in that case, we recommend doing a search on the USPTO.gov website. ###Sign up for the FreshPatents.com FREE Keyword Monitor and check for keyword phrases (ie. "RFID" , "wireless", "web development", "fuel cells" etc.)...You will be notified when new patent applications and inventions are published that match your keywords. Also you can save for later research public patent/invention documents using our FREE Organizer. It takes only 30 seconds to sign up or login.Advertise on FreshPatents.com - Rates & Info###Design/code © 2014 FreshContext LLC/Freshpatents.com.Patent data source: patents published by the United States Patent and Trademark Office (USPTO)Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and may contain additional data/images. FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents and there may be applicable trademarks or servicemarks within the documents.FreshPatents.com Support - Terms & Conditions








IONS Brett P. Monia Insider Trades for Ionis Pharmaceuticals Inc.


































Bulletin






Investor Alert







Tokyo Markets Open in:



US Market Snapshot
Currencies
Commodities


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Ionis Pharmaceuticals Inc.

                  NASDAQ: IONS
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Ionis Pharmaceuticals Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 26, 2017, 4:15 p.m.


IONS

/quotes/zigman/63581627/composite


$
55.08




Change

+0.75
+1.38%

Volume
Volume 19,132
Quotes are delayed by 20 min








/quotes/zigman/63581627/composite
Today's close

$
			54.71
		


$
				54.33
			
Change

-0.38
-0.69%





Day low
Day high
$54.00
$55.98










52 week low
52 week high

            $24.58
        

            $60.01
        


















Insider Activity


Individual




Brett P. Monia



Dr. Brett P. Monia is Senior VP-Drug Discovery & Corporate Development at Ionis Pharmaceuticals, Inc., a Member at American Association for Cancer Research, a Member at American Diabetes Association, a Member at American Association for The Study of Liver Diseases, a Member at American Society of Hematology, and Adjunct Professor at San Diego State University. He is on the Board of Directors at Oligonucleotide Therapeutics Society, Inc.
He received his undergraduate degree from Stockton University and a doctorate degree from the University of Pennsylvania.



Transactions


Date
Shares
Transaction
Value





07/03/2017
309


 
Disposition at $51.35 per share.


15,868


07/01/2017
163


 



6,627


01/17/2017
623


 
Disposition at $46.29 per share.


28,839


01/17/2017
593


 
Disposition at $46.29 per share.


27,450


01/17/2017
733


 
Disposition at $46.29 per share.


33,931


01/17/2017
553


 
Disposition at $46.29 per share.


25,599


01/15/2017
1,594


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
1,518


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
1,875


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
1,415


 
Derivative/Non-derivative trans. at $0 per share.


0


01/03/2017
309


 
Disposition at $48.6 per share.


15,018


01/01/2017
309


 



6,414


12/20/2016
130


 
Disposition at $52.48 per share.


6,823


07/01/2016
309


 



6,414


01/19/2016
747


 
Disposition at $41.46 per share.


30,971


01/19/2016
564


 
Disposition at $41.46 per share.


23,384


01/19/2016
83


 
Disposition at $41.47 per share.


3,443


01/19/2016
210


 
Disposition at $41.46 per share.


8,707


01/19/2016
604


 
Disposition at $41.46 per share.


25,042


01/15/2016
1,518


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
1,875


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
1,415


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
208


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
527


 
Derivative/Non-derivative trans. at $0 per share.


0


01/04/2016
127


 
Disposition at $61 per share.


7,747


01/01/2016
130


 



6,202


07/02/2015
198


 
Disposition at $56.3 per share.


11,148


07/01/2015
127


 



6,170


06/08/2015
7,600


 
Disposition at $66.22 per share.


503,272


06/08/2015
7,600


 
Derivative/Non-derivative trans. at $10.29 per share.


78,204


01/16/2015
714


 
Disposition at $67.96 per share.


48,524


01/16/2015
539


 
Disposition at $67.96 per share.


36,631


01/16/2015
80


 
Disposition at $67.96 per share.


5,437


01/16/2015
201


 
Disposition at $67.96 per share.


13,660


01/15/2015
1,875


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2015
1,415


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2015
208


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2015
527


 
Derivative/Non-derivative trans. at $0 per share.


0


01/02/2015
76


 
Disposition at $62.75 per share.


4,769


01/01/2015
198


 



5,949


08/26/2014
10,000


 
Disposition at $38.14 per share.


381,400


08/26/2014
10,000


 
Derivative/Non-derivative trans. at $7.25 per share.


72,500


08/26/2014
15,000


 
Disposition at $38.14 per share.


572,100


08/26/2014
15,000


 
Derivative/Non-derivative trans. at $10.29 per share.


154,350


08/26/2014
2,344


 
Disposition at $38.14 per share.


89,401


08/26/2014
2,344


 
Derivative/Non-derivative trans. at $11.27 per share.


26,416


07/31/2014
79


 
Disposition at $31.5 per share.


2,489


07/01/2014
76


 



2,295


01/16/2014
202


 
Disposition at $47.08 per share.


9,511


01/16/2014
80


 
Disposition at $47.08 per share.


3,767


01/16/2014
539


 
Disposition at $47.08 per share.


25,377


01/15/2014
528


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2014
208


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2014
1,415


 
Derivative/Non-derivative trans. at $0 per share.


0


01/02/2014
362


 
Disposition at $39.25 per share.


14,209


01/01/2014
79


 



1,911


09/20/2013
18,281


 
Disposition at $35.89 per share.


656,106


09/20/2013
18,281


 
Derivative/Non-derivative trans. at $11.27 per share.


206,026


09/19/2013
1,875


 
Derivative/Non-derivative trans. at $11.27 per share.


21,131


09/19/2013
22,500


 
Disposition at $33.35 per share.


750,375


09/19/2013
22,500


 
Derivative/Non-derivative trans. at $14.47 per share.


325,575


09/19/2013
5,000


 
Disposition at $33.35 per share.


166,750


09/19/2013
5,000


 
Derivative/Non-derivative trans. at $14.65 per share.


73,250


09/19/2013
625


 
Disposition at $33.35 per share.


20,844


09/19/2013
625


 
Derivative/Non-derivative trans. at $15.75 per share.


9,843


09/19/2013
20,000


 
Disposition at $33.96 per share.


679,200


09/19/2013
1,875


 
Disposition at $33.35 per share.


62,532


09/19/2013
20,000


 
Derivative/Non-derivative trans. at $15.38 per share.


307,600


08/26/2013
2,909


 
Disposition at $25.58 per share.


74,413


07/02/2013
215


 
Disposition at $28.69 per share.


6,169


07/01/2013
362


 



3,330


06/11/2013
9,375


 
Disposition at $23.76 per share.


222,750


06/11/2013
9,375


 
Derivative/Non-derivative trans. at $15.75 per share.


147,656


04/22/2013
17,000


 
Disposition at $21.26 per share.


361,420


04/22/2013
17,000


 
Derivative/Non-derivative trans. at $11.12 per share.


189,040


04/19/2013
2,500


 
Disposition at $21.25 per share.


53,125


04/19/2013
2,500


 
Derivative/Non-derivative trans. at $11.12 per share.


27,800


03/05/2013
18,240


 
Disposition at $16.86 per share.


307,527


03/05/2013
18,240


 
Derivative/Non-derivative trans. at $6.81 per share.


124,214


01/16/2013
95


 
Disposition at $14 per share.


1,330


01/16/2013
235


 
Disposition at $14 per share.


3,290


01/15/2013
209


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2013
528


 
Derivative/Non-derivative trans. at $0 per share.


0


01/03/2013
311


 
Disposition at $10.84 per share.


3,372


01/01/2013
215


 



1,907


09/06/2012
12,031


 
Disposition at $15.25 per share.


183,473


09/06/2012
12,031


 
Derivative/Non-derivative trans. at $5.25 per share.


63,162





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Stanley T. Crooke 
Chairman, President & Chief Executive Officer




Ms. B. Lynne Parshall 
Chief Operating Officer & Director




Ms. Elizabeth L. Hougen 
Chief Financial Officer & Senior VP-Finance




Mr. Patrick R. O'Neil 
Secretary, Chief Compliance Officer & SVP-Legal




Ms. Paula  Soteropoulos 
President & CEO-Akcea Therapeutics




Dr. C. Frank Bennett 
Senior Vice President-Antisense Research




Dr. Brett P. Monia 
Senior VP-Drug Discovery & Corporate Development




Dr. Rosanne  Crooke 
Executive Director-Cardiovascular Diseases




Dr. Eugene  Schneider 
Vice President-Clinical Development




Dr. Richard S. Geary 
Senior Vice President-Development




Ms. Sarah  Boyce 
Chief Business Officer




Dr. D. Wade Walke 
VP-Corporate Communications & Investor Relations




Mr. Frederick T. Muto 
Independent Director




Dr. Joseph  Loscalzo 
Independent Director




Mr. Breaux B. Castleman 
Independent Director




Mr. Joseph H. Wender 
Independent Director




Mr. Joseph R. Klein 
Independent Director




Dr. Spencer R. Berthelsen 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/65801738/composite TLT+1.11%


/quotes/zigman/59386294/composite JNUG-5.94%


X




Powered by














Log In




6:40 PM EDT
July 26, 2017


/marketstate/country/us
New York

	After


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
6:14pGraham says Trump is showing weakness in unilateral public spat with Sessions
6:10pFacebook hits 2 billion users, earnings beat boosts stock: Live blog recap
6:04pNew rules for FTSE Russell index provider to exclude Snap, others from benchmarks
5:55pThe Nintendo Switch’s sell-out launch, in many charts
5:51p10 co-workers you should avoid like the plague in meetings
5:51pCommunity Health Systems shares fall after profit warning
5:45pWhat Donald Trump’s battle of wills with Jeff Sessions teaches you about a difficult boss
5:33pStock market ends at record on robust earnings as Fed issues policy update 
5:31pTrump puts his hands together for ‘the late, great Abraham Lincoln’
5:23p2-year Treasury yield falls the most in five weeks after Fed statement
5:20pFor transgender Americans, workplace discrimination isn’t limited to the military
5:09pYour 401(k) match may have some strings attached
5:07pThis is the worst mistake people make at work
5:06pWhy equal-weighted stock-market indexes bounce back faster from bear markets
5:05pNutrisystem shares rally on better-than-expected earnings
5:04pBuffalo Wild Wings drop 9% on 'high' chicken wing costs
5:04pBREAKINGF5 Networks shares fall after weak outlook, revenue miss
5:02pDonald Trump is winning the currency cold war: Pimco
5:00pFacebook hits 2 billion users, earnings beat: Live blog
4:58p‘Game of Thrones’ science: Let’s take a closer look at that greyscale
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,711.01

+97.58
+0.45%





nasdaq

/quotes/zigman/12633936/realtime
6,422.75

+10.57
+0.16%





s&p 500

/quotes/zigman/3870025/realtime
2,477.83

+0.70
+0.03%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































 

Brett P. Monia's involvement in venture capital (via Isis Pharmaceuticals Inc)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/191459-brett-p-moniasection=people&subsection=detail&id=191459




			Search deals by company name, industry, location, investors...			
			




SEARCH


BrettP. MoniaGet alertedif Brett P. Monia gets funded!Brett P. MoniaIsis Pharmaceuticals Inc - Senior Vice President of Antisense Drug DiscoveryDeals involving Brett P. Monia$18,000,000 raised with Isis Pharmaceuticals Inc on October, 2014$3,000,000 raised with Isis Pharmaceuticals Inc on November, 2013$100,000,000 raised with Isis Pharmaceuticals Inc on September, 2013$31,000,000 raised with Isis Pharmaceuticals Inc on December, 2012$201,250,000 raised with Isis Pharmaceuticals Inc on August, 2012Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check Brett P. Monia on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!


Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft






















Loading Your Search Results - PeopleLooker.com























Updating Data On {{nameize fn}}{{#if mi}} {{nameize mi}}{{/if}} {{nameize ln}} {{#validLocation city}}in {{city}}{{#validLocation state}},{{/validLocation}} {{/validLocation}}{{#validLocation state}}{{#unless city}}in {{/unless}}{{uppercase state}}{{/validLocation}}
Important! PeopleLooker uses real public records. The information may be surprising.












Less than 30 seconds remaining


Continue to Results 







Now
We look up all people named {{nameize fn}} {{nameize ln}}.




Next
You pick which one you're looking for.




Then
We search our database for info on them.




Hooray!
You get your report!












Where does {{nameize fn}}{{#if mi}} {{uppercase mi}}{{/if}} {{nameize ln}}
live?
Please help us narrow down your search











All States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming





I'm not sure














Please enter a full name
Please help us narrow down your search







First Name:

Please Enter First Name


Last Name:

Please Enter Last Name












































People Searching Made Easy! | PeopleLooker
































Looking to Find Out About Someone?

Find information you may not get on Google.












State
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming





Search





We respect your privacy.













We've run over


1,000,000


background reports!
Successful background reports!









Access Premium Public Records

Quickly search public records that could otherwise take you weeks or months
to collect. Find friends, relatives, neighbors, or even yourself. Comprehensive
people search reports may contain:




Names
Criminal Records
Date of Birth




Phone Numbers
Addresses
Court Records




Relatives
Email Addresses
Much More!




Names
Criminal Records
Date of Birth
Relatives
Email Addresses




Phone Numbers
Addresses
Court Records
Much More!







The New Way to Find People
More than a regular search engine.

It's the quick and easy way to look people up. Do a deep public record
search to uncover the important information you're looking for. Now you'll
never have to search someone on google again.





































People Searching Made Easy! | PeopleLooker
































Looking to Find Out About Someone?

Find information you may not get on Google.












State
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming





Search





We respect your privacy.













We've run over


1,000,000


background reports!
Successful background reports!









Access Premium Public Records

Quickly search public records that could otherwise take you weeks or months
to collect. Find friends, relatives, neighbors, or even yourself. Comprehensive
people search reports may contain:




Names
Criminal Records
Date of Birth




Phone Numbers
Addresses
Court Records




Relatives
Email Addresses
Much More!




Names
Criminal Records
Date of Birth
Relatives
Email Addresses




Phone Numbers
Addresses
Court Records
Much More!







The New Way to Find People
More than a regular search engine.

It's the quick and easy way to look people up. Do a deep public record
search to uncover the important information you're looking for. Now you'll
never have to search someone on google again.





































People Searching Made Easy! | PeopleLooker
































Looking to Find Out About Someone?

Find information you may not get on Google.












State
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming





Search





We respect your privacy.













We've run over


1,000,000


background reports!
Successful background reports!









Access Premium Public Records

Quickly search public records that could otherwise take you weeks or months
to collect. Find friends, relatives, neighbors, or even yourself. Comprehensive
people search reports may contain:




Names
Criminal Records
Date of Birth




Phone Numbers
Addresses
Court Records




Relatives
Email Addresses
Much More!




Names
Criminal Records
Date of Birth
Relatives
Email Addresses




Phone Numbers
Addresses
Court Records
Much More!







The New Way to Find People
More than a regular search engine.

It's the quick and easy way to look people up. Do a deep public record
search to uncover the important information you're looking for. Now you'll
never have to search someone on google again.





































People Searching Made Easy! | PeopleLooker
































Looking to Find Out About Someone?

Find information you may not get on Google.












State
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming





Search





We respect your privacy.













We've run over


1,000,000


background reports!
Successful background reports!









Access Premium Public Records

Quickly search public records that could otherwise take you weeks or months
to collect. Find friends, relatives, neighbors, or even yourself. Comprehensive
people search reports may contain:




Names
Criminal Records
Date of Birth




Phone Numbers
Addresses
Court Records




Relatives
Email Addresses
Much More!




Names
Criminal Records
Date of Birth
Relatives
Email Addresses




Phone Numbers
Addresses
Court Records
Much More!







The New Way to Find People
More than a regular search engine.

It's the quick and easy way to look people up. Do a deep public record
search to uncover the important information you're looking for. Now you'll
never have to search someone on google again.





















